ArticleMicrobiology spectrum2026
Phasing out India ink: the case for the CrAg LFA in modern practice.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cryptococcal meningitis remains a life-threatening infection, particularly in immunocompromised patients, and timely, accurate diagnosis is essential. In a retrospective review of 489 cerebrospinal fluid samples at a tertiary cancer center, the India ink stain demonstrated low sensitivity (42.9%) compared to lateral flow antigen (100%) and multiplex PCR (100%) methods. These findings support replacing the outdated, labor-intensive India ink test with more accurate, rapid diagnostics to improve detection and patient outcomes.IMPORTANCEThe India ink test has historically been a cornerstone of cryptococcal diagnosis, but its low sensitivity and reliance on subjective interpretation make it increasingly obsolete in modern practice. Continued reliance on India ink risks delayed or missed diagnoses, particularly in immunocompromised patients where early detection is critical. In contrast, the cryptococcal antigen lateral flow assay (CrAg LFA) and other modern diagnostics provide superior sensitivity, ease of use, and reproducibility. Phasing out India ink in favor of the CrAg LFA is essential to align clinical practice with contemporary diagnostic standards and to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.